MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: A case–control analysis in a Moroccan population
Authors:
- Sayeh EzzikouriSESayeh Ezzikouri
- Abdellah Essaid El FeydiAFAbdellah Essaid El Feydi
- Rajae AfifiRARajae Afifi
- Latifa El KihalLKLatifa El Kihal
- Mustapha BenazzouzMBMustapha Benazzouz
- Mohammed HassarMHMohammed Hassar
- Agnès MarchioAMAgnès Marchio
- Pascal PineauPascal Pineau
- Soumaya BenjellounSBSoumaya Benjelloun
- 1 January 2009
- journal article
- Published by Elsevier in Cancer Detection Prevention
- Vol. 32 (5-6) , 380-385
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis CClinical Cancer Research, 2006
- p53 Mutations in hepatocellular carcinoma patients in EgyptInternational Journal of Hygiene and Environmental Health, 2005
- MDM2 is a Central Node in the p53 Pathway: 12 Years and CountingCurrent Cancer Drug Targets, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- The p53–Mdm2 module and the ubiquitin systemSeminars in Cancer Biology, 2003
- mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing IrradiationMolecular and Cellular Biology, 2003
- Post‐translational modifications and activation of p53 by genotoxic stressesEuropean Journal of Biochemistry, 2001
- p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chlorideCancer, 2000
- Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesisProceedings of the National Academy of Sciences, 1998